Adagio Medical's ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference

Ultra-low Temperature Ablation Techniques for Ventricular Tachycardia to be Highlighted in Multiple Presentations

Apr. 17, 2026 at 6:06am

Got story updates? Submit your updates here. ›

A translucent X-ray photograph showing the intricate internal structure of a human heart, with glowing, ghostly lines against a dark background, conceptually representing the advanced cardiac ablation technology featured at the Heart Rhythm 2026 conference.An X-ray view of the human heart reveals the complex internal structures targeted by Adagio's innovative ultra-low temperature ablation technology.Chicago Today

Adagio Medical, a leading innovator in catheter ablation technologies, announced that its Ultra-low Temperature Ablation (ULTA) technologies for the treatment of scar-related ventricular tachycardia will be featured in several presentations at the upcoming Heart Rhythm 2026 conference in Chicago. The ULTA technologies will be showcased through events, scientific presentations, and a late-breaking clinical trial session highlighting the use of ULTA across a broad spectrum of ventricular tachycardias.

Why it matters

Adagio's ULTA technology represents a novel approach to treating complex cardiac arrhythmias like ventricular tachycardia, which can be difficult to manage. The featured presentations at Heart Rhythm 2026 will provide insights into the clinical applications and real-world outcomes of this innovative ablation technique, potentially advancing the standard of care for patients with structural heart disease and recurrent ventricular tachycardia.

The details

Adagio's ULTA technologies will be featured in several events and presentations at Heart Rhythm 2026, including scientific sessions on the use of ultra-low temperature cryoablation for inaccessible ventricular tachycardia, insights from real-world patient data, and pre-clinical studies on accelerating the ablation process. Additionally, a late-breaking clinical trial presentation will showcase the effectiveness and safety of ultra-low temperature ablation of ventricular tachycardia in patients with structural heart disease.

  • The Heart Rhythm 2026 conference will be held from Thursday, April 23 to Sunday, April 26, 2026, in Chicago, Illinois at the McCormick Place Convention Center.
  • Adagio's ULTA technologies will be featured in multiple presentations and events throughout the conference, from April 24 to April 26, 2026.

The players

Adagio Medical Holdings, Inc.

A medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology.

Dr. Druv Sharma

A physician from Vanderbilt University who will present on the use of ultra-low temperature cryoablation for inaccessible ventricular tachycardia in right ventricular cardiomyopathy.

Dr. Borislav Dinov

A physician from Justus Liebig University Giessen, Germany, who will present on the real-world insights and MRI findings from using ultra-low temperature ventricular ablation beyond clinical trials.

Dr. Travis Richardson

A physician from Vanderbilt University who will present on various aspects of ultra-low temperature cryoablation for ventricular tachycardia, including acute outcomes from the FULCRUM-VT trial.

Dr. Atul Verma

A physician from the McGill University Health Centre who will be the presenter for the late-breaking clinical trial presentation on the effectiveness and safety of ultra-low temperature ablation of ventricular tachycardia.

Got photos? Submit your photos here. ›

What they’re saying

“Ultra-Low Temperature Cryoablation for Inaccessible Ventricular Tachycardia in Right Ventricular Cardiomyopathy: First Reported Cases Using a Novel System”

— Dr. Druv Sharma, Vanderbilt University

“Ultra-Low Ventricular Ablation Beyond Clinical Trials: Procedure and MRI Insights from Real-World Patient Series”

— Dr. Borislav Dinov, Justus Liebig University Giessen, Germany

“Ultra-Low Temperature Cryoablation of Ventricular Tachycardia due to Ischemic and Nonischemic Cardiomyopathy: Acute Outcomes of FULCRUM-VT Trial”

— Dr. Travis Richardson, Vanderbilt University

“Effectiveness and Safety of Ultra-Low Temperature Ablation of Ventricular Tachycardia in Patients with Structural Heart Disease: Outcomes of the Pivotal FULCRUM-VT Trial”

— Dr. Atul Verma, McGill University Health Centre; Co-Principal Investigator

What’s next

The results of the FULCRUM-VT trial will be used by Adagio to apply for U.S. Food and Drug Administration (FDA) premarket approval (PMA) for the company's vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated ventricular tachycardia.

The takeaway

Adagio's ULTA technology represents a novel and promising approach to treating complex cardiac arrhythmias like ventricular tachycardia, which can be difficult to manage. The featured presentations at Heart Rhythm 2026 will provide valuable insights into the clinical applications and real-world outcomes of this innovative ablation technique, potentially advancing the standard of care for patients with structural heart disease and recurrent ventricular tachycardia.